Randomized Phase II Trail of Carboplatin and Gemcitabine Untreated Stage IIIB-pleural Effusion and Stage IV Lung Cancer
Subjects enrolled in the study will be placed in one of two treatment arms. All subjects
have a 50-50 chance of being placed into either treatment arm. Treatment Arm 1 will receive
chemotherapy alone, Treatment Arm 2 will receive chemotherapy with dexamethasone given
pre-treatment.
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Determine the effect of dexamethasone pre-treatment on response rates, and survival.
Pre-treatment, pre-cycles 3 & 5 and 4 weeks after last treatment
No
John Rinehart
Principal Investigator
Lucille P. Markey Cancer Center at University of Kentucky
United States: Institutional Review Board
CTN-0501
NCT00247416
August 2005
July 2009
Name | Location |
---|---|
Markey Cancer Center | Lexington, Kentucky 40536 |
Brown Cancer Center | Louisville, Kentucky 40202 |
Commonwealth Cancer Center | Danville, Kentucky 40422 |
St. Claire Regional Medical Center | Morehead, Kentucky 40351 |
Montgomery Cancer Center | Mt. Sterling, Kentucky 40353 |
Owensboro Medical HealthCare System | Owensboro, Kentucky 42303 |
West Kentucky Hematology & Oncology Group, PSC | Paducah, Kentucky 42003 |